Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

Phase 1/2 Completed 20 enrolled The National Retina Institute Genentech, Inc. · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective of this study is to determine the safety \& efficacy of ranibizumab for the treatment of retinal angiomatous proliferation secondary to age related macular degeneration.

Timeline

Start: 2005-08
Primary completion: 2008-04
Completion: 2008-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ranibizumab	Monoclonal antibody	0.3 mg	Intravitreal
Comparator	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

Summary

Timeline

Drugs

Indications